© 1999 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Rapid Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of ApoE in ApoE-Deficient Mice
From the Department of Medicine (K.T., R.T., D.J.R.), University of Pennsylvania School of Medicine, and the Wistar Institute (S.H.C., E.P.), Philadelphia, Pa.
Correspondence to Daniel J. Rader, MD, University of Pennsylvania Medical Center, 409 Stellar Chance Labs, 422 Curie Blvd, Philadelphia, PA 19104. E-mail rader{at}mail.med.upenn.edu
Abstract—Apolipoprotein E (apoE) is a multifunctional protein synthesized by the liver and tissue macrophages. ApoE-deficient mice have severe hyperlipidemia and develop accelerated atherosclerosis on a chow diet. Both liver-derived and macrophage-derived apoEs have been shown to reduce plasma lipoprotein levels and slow the progression of atherosclerosis in apoE-deficient mice, but regression of atherosclerosis has not been demonstrated in this model. We utilized second-generation adenoviruses to achieve hepatic expression of human apoE in chow-fed, apoE-deficient mice with established atherosclerotic lesions of different stages. As expected, hepatic expression of human apoE3 significantly reduced plasma cholesterol levels. Liver-derived apoE also accumulated substantially within preexisting atherosclerotic lesions, indicating that plasma apoE gained access to the arterial intima. Hepatic expression of human apoE3 for 6 weeks resulted in significant quantitative regression of both early fatty streak lesions as well as advanced, complex lesions in both the aortic root and the aortic arch. In addition, hepatic expression of apoE induced substantial morphological changes in lesions, including decreased foam cells and increased smooth muscle cells and extracellular matrix content. In parallel, human apoE4 and apoE2 were also expressed in the liver by using recombinant adenoviruses. ApoE4 reduced cholesterol levels to the same extent as did apoE3 and also prevented progression but did not induce significant regression of preexisting lesions. ApoE2 reduced cholesterol levels to a lesser degree than did apoE3 and apoE4 and lesion progression was reduced, but regression was not induced. In summary, (1) regression of preexisting atherosclerotic lesions in apoE-deficient mice can be rapidly induced by hepatic expression of apoE, despite the absence of macrophage-derived apoE; (2) the morphological changes seen in this model of regression resemble those in other animal models, induced over longer periods of time; (3) liver-derived apoE gained access to and was retained by intimal atherosclerotic lesions; and (4) apoE4 was less effective in inducing regression, despite its effects on plasma lipoproteins that were similar to those of apoE3. The rapid regression of preexisiting atherosclerotic lesions induced by apoE gene transfer in apoE-deficient mice could provide a convenient murine model for investigation of the molecular events associated with atherosclerosis regression.
Key Words: atherosclerosis • regression • gene transfer • adenoviral vectors • apolipoproteins
This article has been cited by other articles:
 |
|
 |
|
  L. Zhao, E. Lee, A. M. Zukas, M. K. Middleton, M. Kinder, P. S. Acharya, J. A. Hall, D. J. Rader, and E. Pure CD44 Expressed on Both Bone Marrow-Derived and Non-Bone Marrow-Derived Cells Promotes Atherogenesis in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1283 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Atkinson, K. R. Coenen, M. R. Plummer, M. L. Gruen, and A. H. Hasty Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E284 - E290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kitajima, D. H.L. Marchadier, G. C. Miller, G.-p. Gao, J. M. Wilson, and D. J. Rader Complete Prevention of Atherosclerosis in ApoE-Deficient Mice by Hepatic Human ApoE Gene Transfer With Adeno-Associated Virus Serotypes 7 and 8 Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1852 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. MacDougall, F. Kramer, P. Polinsky, S. Barnhart, B. Askari, F. Johansson, R. Varon, M. E. Rosenfeld, K. Oka, L. Chan, et al. Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Combined with a Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice Am. J. Pathol., June 1, 2006; 168(6): 2064 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Heeren, U. Beisiegel, and T. Grewal Apolipoprotein E Recycling: Implications for Dyslipidemia and Atherosclerosis Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 442 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Raffai, S. M. Loeb, and K. H. Weisgraber Apolipoprotein E Promotes the Regression of Atherosclerosis Independently of Lowering Plasma Cholesterol Levels Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 436 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Trogan, Z. A. Fayad, V. V. Itskovich, J.-G. S. Aguinaldo, V. Mani, J. T. Fallon, I. Chereshnev, and E. A. Fisher Serial Studies of Mouse Atherosclerosis by In Vivo Magnetic Resonance Imaging Detect Lesion Regression After Correction of Dyslipidemia Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1714 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kim, S. Xie, S.-D. Yeh, Y.-F. Lee, L. L. Collins, Y.-C. Hu, C.-R. Shyr, X.-M. Mu, N.-C. Liu, Y.-T. Chen, et al. Disruption of TR4 Orphan Nuclear Receptor Reduces the Expression of Liver Apolipoprotein E/C-I/C-II Gene Cluster J. Biol. Chem., November 21, 2003; 278(47): 46919 - 46926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mertens, P. Verhamme, J. K. Bielicki, M. C. Phillips, R. Quarck, W. Verreth, D. Stengel, E. Ninio, M. Navab, B. Mackness, et al. Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice: LCAT Gene Transfer Decreases Atherosclerosis Circulation, April 1, 2003; 107(12): 1640 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hara, T. Matsushima, H. Satoh, N. Iso-o, H. Noto, M. Togo, S. Kimura, Y. Hashimoto, and K. Tsukamoto Isoform-Dependent Cholesterol Efflux From Macrophages by Apolipoprotein E Is Modulated by Cell Surface Proteoglycans Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 269 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Choudhury, V. Fuster, J. J. Badimon, E. A. Fisher, and Z. A. Fayad MRI and Characterization of Atherosclerotic Plaque: Emerging Applications and Molecular Imaging Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1065 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shi, X. Wang, K. Tangchitpiyanond, J. Wong, Y. Shi, and A. J. Lusis Atherosclerosis in C3H/HeJ Mice Reconstituted With Apolipoprotein E-Null Bone Marrow Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 650 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Raffai and K. H. Weisgraber Hypomorphic Apolipoprotein E Mice. A NEW MODEL OF CONDITIONAL GENE REPAIR TO EXAMINE APOLIPOPROTEIN E-MEDIATED METABOLISM J. Biol. Chem., March 22, 2002; 277(13): 11064 - 11068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Harris, I. R. Graham, S. Schepelmann, A. K. Stannard, M. L. Roberts, B. L. Hodges, V. Hill, A. Amalfitano, D. G. Hassall, J. S. Owen, et al. Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1-, E3-, polymerase-] adenovirus vector expressing human apoE Hum. Mol. Genet., January 1, 2002; 11(1): 43 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-a. Kawashiri, Y. Zhang, D. Usher, M. Reilly, E. Puré, and D. J. Rader Effects of coexpression of the LDL receptor and apoE on cholesterol metabolism and atherosclerosis in LDL receptor-deficient mice J. Lipid Res., June 1, 2001; 42(6): 943 - 950. [Abstract] [Full Text]
|
|
|
|
|
|
J. F. Bentzon, E. Skovenborg, C. Hansen, J. Moller, N. S.-C. de Gaulejac, J. Proch, and E. Falk Red Wine Does Not Reduce Mature Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, March 27, 2001; 103(12): 1681 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Stein and O. Stein Does Therapeutic Intervention Achieve Slowing of Progression or Bona Fide Regression of Atherosclerotic Lesions? Arterioscler Thromb Vasc Biol, February 1, 2001; 21(2): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shi, X. Wang, N. J. Wang, W. H. McBride, and A. J. Lusis Effect of Macrophage-Derived Apolipoprotein E on Established Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2261 - 2266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Tagalakis, I. R. Graham, D. R. Riddell, J. G. Dickson, and J. S. Owen Gene Correction of the Apolipoprotein (Apo) E2 Phenotype to Wild-type ApoE3 by in Situ Chimeraplasty J. Biol. Chem., April 13, 2001; 276(16): 13226 - 13230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Tangirala, D. Pratico, G. A. FitzGerald, S. Chun, K. Tsukamoto, C. Maugeais, D. C. Usher, E. Pure, and D. J. Rader Reduction of Isoprostanes and Regression of Advanced Atherosclerosis by Apolipoprotein E J. Biol. Chem., January 5, 2001; 276(1): 261 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Klezovitch, M. Formato, G. M. Cherchi, K. H. Weisgraber, and A. M. Scanu Structural Determinants in the C-terminal Domain of Apolipoprotein E Mediating Binding to the Protein Core of Human Aortic Biglycan J. Biol. Chem., June 16, 2000; 275(25): 18913 - 18918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shi, X. Wang, K. Tangchitpiyanond, J. Wong, Y. Shi, and A. J. Lusis Atherosclerosis in C3H/HeJ Mice Reconstituted With Apolipoprotein E-Null Bone Marrow Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 650 - 655. [Abstract] [Full Text] [PDF]
|
|